Abstract
[Objective]: To explore the roles of Human Leukocyte Interferon (HLI) and Receptor for Advanced Glycation Endproducts (RAGE) in the occurrence and development of systemic lupus erythematosus (SLE), as well as their associations with the disease activity and clinical symptoms of SLE, and to evaluate the clinical application value of their detection.
[Methods]: The levels of serum RAGE and HLI in SLE patients were detected via ELISA. The immunomagnetic bead method was used to measure the amounts of interleukin (IL)-1β, IL-2, IL-4, IL-5, and IL-6. Serum HLI and RAGE levels in the active and inactive groups were assessed to gauge the effectiveness of the trial.
[Results]: The SLE group had higher levels of HLI and RAGE than the RA group (P<0.05), while the RA group had lower levels of IL-2 and IL-6 (P<0.05). The active group had higher levels of RAGE, IL-6, and HLI than the inactive group (P<0.05). Positive correlations were found between RAGE and HLI (r=0.79, P=0.015) and between RAGE and HLI and the SLEDAI (r=0.65, P=0.016; r=0.44, P=0.034). RAGE is related to the cytokines IL-1β, IL-4 and IL-5, whereas HLI is related to IL-1β and IL-4.
[Conclusion]: HLI and RAGE support one another and play a role in the onset and progression of SLE. Both HLI and RAGE are associated with disease activity and clinical manifestations such as fever and kidney damage in patients with SLE. Their detection has great application value in differentiating active and inactive SLE patients in clinical practice.
Keywords
Array
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.